These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22218323)

  • 1. Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy.
    Kitaoka H; Kubo T; Baba Y; Yamasaki N; Matsumura Y; Furuno T; Doi YL
    J Cardiol; 2012 Mar; 59(2):209-14. PubMed ID: 22218323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure.
    Fujimoto N; Onishi K; Sato A; Terasaki F; Tsukada B; Nozato T; Yamada T; Imanaka-Yoshida K; Yoshida T; Ito M; Hiroe M
    J Card Fail; 2009 Dec; 15(10):898-905. PubMed ID: 19944367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy.
    Terasaki F; Okamoto H; Onishi K; Sato A; Shimomura H; Tsukada B; Imanaka-Yoshida K; Hiroe M; Yoshida T; Kitaura Y; Kitabatake A;
    Circ J; 2007 Mar; 71(3):327-30. PubMed ID: 17322629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction.
    Sato A; Aonuma K; Imanaka-Yoshida K; Yoshida T; Isobe M; Kawase D; Kinoshita N; Yazaki Y; Hiroe M
    J Am Coll Cardiol; 2006 Jun; 47(11):2319-25. PubMed ID: 16750702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of tenascin-C variants in congestive heart failure patients: comparative analysis of ischemic, dilated, and hypertensive cardiomyopathy.
    Franz M; Berndt A; Grün K; Kuethe F; Fritzenwanger M; Figulla HR; Jung C
    Clin Lab; 2014; 60(6):1007-13. PubMed ID: 25016707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis.
    Franz M; Berndt A; Neri D; Galler K; Grün K; Porrmann C; Reinbothe F; Mall G; Schlattmann P; Renner A; Figulla HR; Jung C; Küthe F
    Int J Cardiol; 2013 Oct; 168(6):5344-51. PubMed ID: 23998545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy.
    Kubo T; Kitaoka H; Yamanaka S; Hirota T; Baba Y; Hayashi K; Iiyama T; Kumagai N; Tanioka K; Yamasaki N; Matsumura Y; Furuno T; Sugiura T; Doi YL
    J Am Coll Cardiol; 2013 Oct; 62(14):1252-1259. PubMed ID: 23623916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction.
    Sato A; Hiroe M; Akiyama D; Hikita H; Nozato T; Hoshi T; Kimura T; Wang Z; Sakai S; Imanaka-Yoshida K; Yoshida T; Aonuma K
    J Card Fail; 2012 Jun; 18(6):480-6. PubMed ID: 22633306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of metalloproteinases on left ventricular remodeling and heart failure events in patients with hypertrophic cardiomyopathy.
    Kitaoka H; Kubo T; Okawa M; Hayato K; Yamasaki N; Matsumura Y; Doi YL
    Circ J; 2010 Jun; 74(6):1191-6. PubMed ID: 20453389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy.
    Niebroj-Dobosz I; Madej-Pilarczyk A; Marchel M; Sokołowska B; Hausmanowa-Petrusewicz I
    Clin Chim Acta; 2011 Aug; 412(17-18):1533-8. PubMed ID: 21596026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypertrophic cardiomyopathy with dilatation of the left ventricle and congestive heart failure: comparison with postmyocarditis cardiomegaly and hypertensive heart failure].
    Kawanishi H; Yokota Y; Hayakawa M; Kaku K; Kumaki T; Matsumoto K; Fujitani K; Ito Y; Inoh T; Fukuzaki H
    J Cardiogr; 1983 Sep; 13(3):537-50. PubMed ID: 6235295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy: report from the registry data in Japan.
    Goto D; Kinugawa S; Hamaguchi S; Sakakibara M; Tsuchihashi-Makaya M; Yokota T; Yamada S; Yokoshiki H; Tsutsui H;
    J Cardiol; 2013 Jan; 61(1):65-70. PubMed ID: 23078864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Serum Levels of Fetal Tenascin-C Variants in Patients with Pulmonary Hypertension: Novel Biomarkers Reflecting Vascular Remodeling and Right Ventricular Dysfunction?
    Rohm I; Grün K; Müller LM; Kretzschmar D; Fritzenwanger M; Yilmaz A; Lauten A; Jung C; Schulze PC; Berndt A; Franz M
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29117120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma indoxyl sulfate levels predict cardiovascular events in patients with mild chronic heart failure.
    Imazu M; Fukuda H; Kanzaki H; Amaki M; Hasegawa T; Takahama H; Hitsumoto T; Tsukamoto O; Morita T; Ito S; Kitakaze M
    Sci Rep; 2020 Oct; 10(1):16528. PubMed ID: 33020564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new predictor of mortality in hemodialysis patients; Tenascin-C.
    Ulusoy S; Ozkan G; Menteşe A; Guvercin B; Caner Karahan S; Yavuz A; Altay DU
    Life Sci; 2015 Nov; 141():54-60. PubMed ID: 26390818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Serum Omentin-1 Levels for the Prediction of Adverse Cardiac Events in Patients with Hypertrophic Cardiomyopathy.
    Yıldız SS; Sahin I; Cetinkal G; Aksan G; Kucuk SH; Keskin K; Cetin S; Sigirci S; Avcı İİ; Kilci H; Kiliçkesmez K
    Med Princ Pract; 2018; 27(2):107-114. PubMed ID: 29402833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of Non-Dilated Left Ventricular Size and Mitral Regurgitation in Patients With Dilated Phase of Hypertrophic Cardiomyopathy.
    Kubo T; Baba Y; Hirota T; Tanioka K; Yamasaki N; Doi YL; Kitaoka H
    Int Heart J; 2017 Feb; 58(1):63-68. PubMed ID: 28077817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma metalloproteinase levels and left ventricular remodeling in hypertrophic cardiomyopathy in patients with an identical mutation.
    Kitaoka H; Kubo T; Okawa M; Takenaka N; Baba Y; Yamasaki N; Matsumura Y; Furuno T; Doi YL
    J Cardiol; 2011 Nov; 58(3):261-5. PubMed ID: 21890325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort.
    Gellen B; Thorin-Trescases N; Thorin E; Gand E; Sosner P; Brishoual S; Rigalleau V; Montaigne D; Javaugue V; Pucheu Y; Gatault P; Piguel X; Hadjadj S; Saulnier PJ;
    Diabetologia; 2020 May; 63(5):915-923. PubMed ID: 32040670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.